This article was triggered by a beverage-induced discussion I had with Martin Eglitis at BIO-Europe earlier this month. In my licensing courses, I spend a bit of time talking about the probability…
In Part One of his series, Dr. Garrett Lindemann discussed some of the challenges facing Wyoming as it grows its life science industry. In Part Two of this series, Dr. Lindemann highlights some of…
Earlier this week, The Economist travels over well-trod ground in an article on pharmaceutical industry M&A: It used to be all about achieving sheer scale, and building a broad portfolio…
Today we learn that generics giant Mylan has entered into a partnership with India-based Biocon to focus on insulin analog biosimilars: Under the terms of this collaboration, Mylan will have…
Happy New Year! For many companies, 2012 was a challenging year. How will 2013 play out? Here are a few ideas we've discussed internally as we look forward to 2013:…
We've had the good fortune to work with a biosimilars client this year. Working in this space has given us an opportunity to read and listen to many experts in…
Thank goodness for Twitter. How else can one keep up with all of the news and happenings in our industry during the "slow" month of July? Here are a few…
The past seven days have brought us two very interesting transactions. First, on March 14, Lyon-based Flamel announced their acquisition of St. Louis-based Eclat Pharmaceuticals. The press release contains a…
Earlier this week we learned that Pfizer will return to Biocon rights to biosimilar versions of various insulin derivatives: As of March 12, 2012, all rights licensed to Pfizer will…
UPDATE (21 February) - Here is a decent video interview of Rachel Sherman, head of the Office of Medical Policy for the FDA, on the Biosimilar guidelines: BioCentury This Week Today…